GAITHERSBURG, Md., June 04, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX) today announced that John J. Trizzino, Senior Vice President, Chief Business Officer and Chief Financial Officer, will join other vaccine industry leaders for a panel discussion at the 2019 BIO International Convention. Taking place in Philadelphia, Pennsylvania on Wednesday, June 5 at 11:00 a.m. EDT, the panel will cover the future of influenza vaccines, including regulatory process opportunities and challenges, real-world evidence, and investment costs and data that informs market uptake to help fulfill global health community goals for influenza prevention.
Details for the panel are as follows:
|Title:||“The Future of Influenza Vaccines”|
|Date and Time:||Wednesday, June 5, 11:00 a.m.|
|Moderator:||Bruce Gellin, M.D., M.P.H., President, Global Immunization, Sabin Vaccine Institute|
|Panelists:||Mr. Trizzino |
Luciana Borio, Vice President, Technical Staff, In-Q-Tel
Bruce D. Clark, Ph.D., Chief Executive Officer and President, Medicago, Inc.
Peter Marks, M.D., Ph.D., Director of the Center for Biologics Evaluation and Research (CBER) at Food and Drug Administration
Gordon Naylor, President, Seqirus
Paul Radspinner, President and Chief Executive Officer, FluGen Inc.
Novavax, Inc. (NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Its two priority programs are ResVax™, its RSV vaccine for infants via maternal immunization, and NanoFlu™, its quadrivalent influenza nanoparticle vaccine. Novavax’ proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.
Senior Manager, Investor & Public Relations